IL17RB and neoplasm: Depletion of IL-17B or IL-17RB by shRNA or treatment with anti-IL-17B or anti-IL-17RB antibodies reduces CFPAC-1 and BxPC3 pancreatic cell line colony formation, invasion, tumor growth, and metastasis in xenograft models.